Robyn Karnauskas Recent News
A Decade Of Sales Growth Lies Ahead For Vertex Pharmaceuticals
Bluebird News A Positive For Juno, Kite Pharma
Citi Starts Calithera Biosciences At Sell On Cash Burn And Lack Of Near-Term Catalysts
Citi Launches Positive Coverage On Five Prime Therapeutics
Citi Sees 26% Upside In TESARO On The Strength Of Trial Data
Citi Sees Kadmon's Trials As 'Risky,' Initiates With Neutral Rating
Citigroup Upgrades Bellicum Pharma, Sees Clearer Pathway For BPX-501 Approval
Citi Raises TESARO Price Target 38%, Sees 16.3% Upside
Alexion Pharma Brexit Selloff Creates An Entry Point: Trading At 'Dark-Sky' Valuation
Regeneron CEO And CFO Met With Citi: Here Are The Takeaways
Lingo Failure Leads Citi To Downgrade Biogen
Solid Potential For Gilead To Beat Estimates And Raise Guidance: Here's How
Has A Biotech Recovery Started Yet?
Citi Surprised, Confused Amid Report Biogen May Divest Hemophilia Unit
Citi: Buy Celgene, Gilead, Biogen And Regeneron As Biotechs Recover
Wall Street's Best Think Gilead Will Continue To Outperform The Market
Wall Street Mixed On Biogen Before Earnings
Deutsche Bank Bullish On Biogen: New Data Doesn't Change Probability Of Success For Alzheimer's
BioMarin's Results Are In: What Do They Mean?
Deutsche Sees Cancer Treatment Home Run At Infinity Pharmaceuticals
This Data Offers Insight Into Gilead Sales
Gilead Alert: What Deutsche Bank Is Saying
Why BioMarin Pharmaceutical Is Surging